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Abstract
Background This study aimed to determine the incidence of new onset hepatic steatosis after neoadjuvant chemotherapy for
pancreatic cancer and its impact on outcomes after pancreatoduodenectomy.
Methods Retrospective review identified patients who received neoadjuvant chemotherapy for pancreatic adenocarcinoma and
underwent pancreatoduodenectomy from 2013 to 2018. Preoperative computed tomography scans were evaluated for the
development of hepatic steatosis after neoadjuvant chemotherapy. Hypoattenuation included liver attenuation greater than or
equal to 10 Hounsfield units less than tissue density of spleen on noncontrast computed tomography and greater than or equal to
20 Hounsfield units less on contrast-enhanced computed tomography.
Results One hundred forty-nine patients received neoadjuvant chemotherapy for a median of 5 cycles (interquartile range (IQR),
4–6). FOLFIRINOX was the regimen in 78% of patients. Hepatic steatosis developed in 36 (24%) patients. The median time
from neoadjuvant chemotherapy completion to pancreatoduodenectomy was 40 days (IQR, 29–51). Preoperative biliary stenting
was performed in 126 (86%) patients. Neoadjuvant radiotherapy was delivered to 23 (15%) patients. Female gender, obesity, and
prolonged exposure to chemotherapy were identified as risk factors for chemotherapy-associated hepatic steatosis. Compared
with control patients without neoadjuvant chemotherapy-associated hepatic steatosis, patients developing steatosis had similar
rates of postoperative pancreatic fistula (8% (control) vs. 4%, p = 0.3), delayed gastric emptying (8% vs. 14%, p = 0.4), andmajor
morbidity (11% vs. 15%, p = 0.6). Ninety-day mortality was similar between groups (8% vs. 2%, p = 0.08).
Conclusion Hepatic steatosis developed in 24% of patients who received neoadjuvant chemotherapy but was not associated with
increased morbidity or mortality after pancreatoduodenectomy.
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Introduction
Pancreatic cancer is one of the deadliest solid malignan-
cies and represents the third leading cause of cancer-
related deaths in the USA.
1, 2 Pancreatic ductal adeno-
carcinoma (PDAC) may present with vague and nonspe-
cific symptoms and is often diagnosed with advanced
stage of disease. Although surgical extirpation offers
the greatest opportunity for cure, only 10–20% of pa-
tients have resectable disease at the time of diagnosis.
3,
4 In patients with borderline resectable or locally ad-
vanced pancreatic cancer, neoadjuvant chemotherapy
(NAC) is recommended to improve patient selection
for operative resection.
5, 6 Multiagent chemotherapy, in-
cluding 5-fluorouracil, leucovorin, oxaliplatin, and
irinotecan (FOLFIRINOX) or gemcitabine with nab-pac-
litaxel, offers improvement in overall survival but can
have harmful side effects including neurotoxicity and
hepatotoxicity such as steatosis or steatohepatitis.
7–11
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The impact of chemotherapy-associated hepatic steatosis
on morbidity and mortality after pancreatoduodenectomy
(PD) is not well described. Postoperative morbidity in pa-
tients undergoing PD remains as high as 40% despite careful
patient selection and experience in perioperative care.
12–14
While exposure to chemotherapy and chemoradiotherapy
does not seem to have a major negative impact on early op-
erative outcomes after PD, direct and indirect effects of neo-
adjuvant therapy on pancreatectomy-specific outcomes re-
quire further investigation.
15–17
Direct chemotherapy-related effects, including hepatic
steatosis, may result in liver injury and impairment of hepatic
function and lead to worse surgical outcomes after PD. The
purpose of this study was to identify the incidence of hepatic
steatosis after neoadjuvant chemotherapy and determine its
impac t on ea r l y pos tope r a t i v e ou t comes a f t e r
pancreatoduodenectomy.
Methods
Patient Population
All patients who underwent PD between 2013 and 2018
were prospectively recorded and retrospectively
reviewed. Patients receiving NAC for PDAC were in-
cluded for analysis. Exclusion criteria included patients
who did not receive NAC, those with hepatic steatosis
indicative of underlying fatty liver disease prior to
NAC, and also patients without imaging available for
review. Informed consent was obtained for all patients
maintained in the pancreatectomy database, and institu-
tional approval was gained through the Indiana
University Institutional Review Board.
Definitions and Outcomes
All monitored American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP)
variables were evaluated, and the clinical database was
augmented through individual patient electronic medical
record review. Demographic information included pa-
tient age, sex, race, body mass index (BMI), and co-
morbidities. The type and duration of NAC received,
interval between last cycle of NAC and surgery, and
preoperative diagnostic imaging were manually reviewed
and documented. Preoperative laboratory values were
recorded when available within 30 days of the operative
date. Other clinical variables of interest included the
presence of preoperative obstructive jaundice with or
without biliary stenting within 30 days prior to surgery,
operative wound classification, use of wound barrier
device, duration of operation, pancreatectomy-specific
factors, and vascular resection with reconstruction.
Postoperative outcomes included morbidity and mortal-
ity, postoperative pancreatic fistula (POPF), delayed gas-
tric emptying (DGE), transfusion requirement, infectious
complications, venous thromboembolism, renal insuffi-
ciency, major cardiovascular events, percutaneous drain
placement, operative re-exploration, length of stay
(LOS), nonhome discharge, and 30-day hospital readmis-
sion. The International Study Group for Pancreatic
Surgery (ISGPS) 2007 and 2016 criteria were used to
define DGE and postoperative pancreatic fistula,
respectively.
18, 19 Major morbidity was defined as POPF
grade B or C, DGE grade B, sepsis, or Clavien-Dindo
class III or above postoperative complications.
20, 21
Mortality was recorded as any death within 30 or 90 days
of PD.
Preoperative computed tomography (CT) scans before and
after NAC were evaluated by a single radiologist for the de-
velopment of radiographic hepatic steatosis that was defined
by relative hypoattenuation of liver parenchyma density com-
pared with spleen. Hypoattenuation was defined as liver atten-
uation greater than or equal to 10 Hounsfield units (HU) less
than that of spleen on noncontrast CT and greater than or equal
to 20 HU less on contrast-enhanced CT,
22
as is routine practice
at our institution. Only patients that developed moderate-to-
severe hepatic steatosis were included in the hepatic steatosis
patient cohort. Pre- and post-contrast CT imaging may differ-
entiate different degrees of hepatic steatosis,
23
although stan-
dardized attenuation cutoff values for mild, moderate, and
severe steatosis are not available. Moderate and severe
steatosis was therefore graded qualitatively by the
radiologist,
24
with severe steatosis defined as uniform, marked
hypodensity of the liver compared to the spleen. Spleen mea-
surements before and after NAC were objectively measured
by the radiologist in its largest craniocaudal axis on the coro-
nal reformats.
Statistics
Two-way analysis was used to compare preoperative charac-
teristics, intraoperative details, and postoperative outcomes
between the subgroups of patients with (study group) or with-
out (control group) NAC-associated hepatic steatosis. Chi-
square test was used for categorical variables, and Student’s
T test was used for continuous variables.Multivariable logistic
regression models were used to evaluate the effect of hepatic
steatosis on 30-day mortality, overall morbidity, and major
morbidity while adjusting for other confounders. A p value
of less than 0.05 was considered significant. All analyses were
conducted with Stata 11.0 statistical software (College
Station, TX).
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Results
Preoperative Demographics
A total of 149 patients with PDAC receivedNAC for amedian
of 5 cycles (IQR, 4–6 cycles). Ten patients were excluded
because of evidence of hepatic steatosis prior to NAC.
FOLFIRINOX was the chemotherapy regimen in 78% of pa-
tients, and the next most common NAC combination was
gemcitabine plus nab-paclitaxel. Hepatic steatosis developed
in 36 (24%) patients after NAC (89% FOLFIRINOX vs. 11%
gemcitabine + nab-paclitaxel). Patients with hepatic steatosis
were significantly more likely to be obese, female, and have
more prolonged exposure to chemotherapy, Table 1.
Peri- and Postoperative Outcomes
The median time from completion of NAC to PD was 40 days
(IQR, 29–51 days). The majority (86%) of patients had pre-
operative placement of a biliary stent, and radiation therapy
was used in less than 20% of patients. Pancreatic gland texture
and objective evidence of portal hypertension, including
splenomegaly and thrombocytopenia, at the time of operation
were not associated with the development of hepatic steatosis
after NAC, Table 1. Perioperative variables were similar be-
tween groups except for more frequent use of a wound pro-
tector in the cohort of patients who did not develop steatosis,
Table 1. On bivariate analysis, major morbidity, overall mor-
bidity, and 30- and 90-day mortality were not statistically
different between the hepatic steatosis and nonsteatosis
groups. Hospital LOS was nearly 2 days longer in the group
without hepatic steatosis, but the remaining postoperative out-
comes did not differ between the two groups, Table 2.
Multivariable logistic regression models were performed
for major morbidity, overall morbidity, and mortality,
Table 3. In patients developing steatosis, no difference was
observed in major morbidity, overall morbidity, and mortality
after PD compared with patients without NAC-associated he-
patic steatosis.
Discussion
In this series of patients undergoing PD after neoadjuvant
chemotherapy, the incidence of neoadjuvant chemotherapy-
associated hepatic steatosis was 24%. Identified risk factors
for the development of hepatic steatosis in this series included
female sex, obesity, and prolonged duration of exposure to
NAC. Hepatic steatosis was associated the timeline from last
of NAC to PD. Despite the development of radiographically
detectable hepatic steatosis, the frequency of postoperative
morbidity or mortality was not increased for patients under-
going PD.
The association between steatosis and nonalcoholic
steatohepatitis (NASH) on liver histopathology and radio-
graphic hepatic steatosis remains unclear. Furthermore, micro-
scopic changes indicative of liver injury after NAC and the
impact on postoperative morbidity and mortality after PD
have not been studied. The impact of hepatic steatosis on
postoperative morbidity and mortality has been most thor-
oughly investigated for patients undergoing hepatic resection
for colorectal metastases. Studies have shown mixed results
with regard to differences in postoperative morbidity or mor-
tality after liver resection in patients developing hepatic injury
from NAC .
25–28 An association between hepatic steatosis and
increased infectious complications after hepatic resection may
exist.
29
However, this association was not observed in this
current study of patients undergoing PD after NAC exclusive-
ly. Several other studies have shown an increase in major
postoperative morbidity in patients undergoing hepatectomy
with steatohepatitis,
30–32 but future investigations will need to
address the impact of histologically proven NAC-associated
hepatic steatohepatitis on pancreatic surgery.
The correlations between hepatotoxicity and duration of
NAC and the interval between treatment completion and sur-
gery have been studied previously. Hepatectomy within 4
weeks of NAC completion was associated with increased
complications compared with waiting 5–6 weeks.
33
However, the interval between neoadjuvant therapy and PD
for patients with pancreatic cancer did not impact short-term
morbidity or mortality.
34
In the present study, the median in-
terval from NAC to pancreatectomy was 5.7 weeks and was
not influenced by the development of NAC-associated hepatic
steatosis. Based on these data, this timeline of PD after NAC is
assumed to be safe even for patients developing NAC-
associated hepatic steatosis
FOLFIRINOX, the NAC regimen used most frequently in
the present study, is a combination of drugs that includes 5-
fluorouracil, leucovorin, irinotecan, and oxaliplatin. The un-
derlying mechanisms of drug metabolism and induced hepa-
totoxicity are poorly understood. A recent meta-analysis
found that the nature of injury from NAC is specific to the
regimen of agents used. Irinotecan-based therapy tends to
cause steatohepatitis, whereas oxaliplatin leads to sinusoidal
venular obstruction.
11
The reversibility of chemotherapy-
induced steatohepatitis may require several months.
35
Although this study found no increase in short-term mortality
or morbidity in patients undergoing pancreatectomy with he-
patic steatosis, long-term outcomes beyond 30 days will need
further investigation. NAC-associated hepatic steatosis may
mimic the organ-specific metabolism and histologic changes
observed in nonalcoholic fatty liver disease (NAFLD).
36
NAFLD, one manifestation of a metabolic syndrome, may
progress to liver fibrosis, cirrhosis, or portal hypertension.
37,
38 Thus, chemotherapy-induced hepatic steatosis may result in
some degree of portal hypertension and influence vein
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Table 1 Baseline comparison of pre- and perioperative factors
− Hepatic steatosis
N (%) or N (SD)
+ Hepatic steatosis
N (%) or N (SD)
P value
Number of patients 103 (69) 36 (31) --
Preoperative factors
Age > = 70 (years) 33 (32) 6 (17) 0.07
Male sex 63 (61) 11 (31) 0.002
Race (white) 90 (87) 33 (92) 0.5
BMI > = 30 (kg/m2) 24 (23) 15 (42) 0.035
ASA > = 3 101 (98) 36 (100) 0.4
Diabetes 47 (46) 10 (28) 0.06
Tobacco use 34 (33) 8 (22) 0.2
COPD 5 (5) 1 (3) 0.6
Dyspnea 7 (7) 3 (8) 0.8
Hypertension 55 (53) 19 (53) 0.9
Disseminated cancer 3 (3) 1 (3) 0.9
Steroid use 2 (2) 0 (0) 0.4
> 10% weight loss 32 (31) 8 (22) 0.3
Bleeding disorder 2 (2) 1 (3) 0.8
Albumin > = 3 (mg/dL) 90 (90) 36 (100) 0.049
Platelet count (median, IQR) 225 (177–291) 202 (149–253) 0.2
Pneumonia or COPD 6 (6) 1 (3) 0.5
Spleen size after NAC (cm) (median, IQR) 10.9 (9.8–12.9) 11.1 (9.5–12.9) 0.9
Change in spleen size pre to post NAC (cm) (median, IQR) 0.5 (0–1.1) 0.8 (0.2–1.1) 0.4
Obstructive jaundice 14 (14) 1 (3) 0.07
Biliary Endostent placement 87 (85) 32 (89) 0.5
Radiation 14 (14) 9 (25) 0.1
Chronic pancreatitis 37 (36) 12 (33) 0.8
Chemotherapy duration (days), median (IQR) 59 (41–79) 75 (50–102) 0.009
Chemotherapy (FOLFIRINOX) 71 (74) 32 (89) 0.07
Duration from chemotherapy to operation (days), median (IQR) 40 (29–50) 39 (29–51) 0.9
Perioperative factors
Contaminated/dirty wound 18 (18) 4 (11) 0.5
Wound barrier device 102 (99) 33 (92) 0.023
Pancreatic duct size 0.9
> 6 mm 19 (20) 7 (21)
3–6 mm 61 (65) 22 (65)
< 3 mm 14 (15) 5 (15)
Gland texture 0.6
Hard 58 (60) 22 (65)
Intermediate 17 (18) 7 (21)
Soft 22 (23) 5 (15)
Pancreatic reconstruction 0.6
Duct to mucosa 97 (94) 33 (92)
Other 6 (6) 3 (8)
Vascular resection 25 (24) 13 (36) 0.2
Operative duration (minutes) 303 (89.9) 330 (93) 0.1
ASAAmerican Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease, dL deciliter, IQR interquartile range,
cm centimeter, kg kilogram, mg milligram, mm millimeter, NAC neoadjuvant chemotherapy. Bold indicates significance
J Gastrointest Surg
patency rates after portal vein or superior mesenteric vein
reconstruction. However, objective measures of portal hyper-
tension, including splenomegaly and hypersplenism, were not
found in the patients who developed hepatic steatosis.
Furthermore, this study did not reveal a statistically significant
difference in vein patency rates for the patient group who
developed hepatic steatosis after NAC. Patients who develop
fatty liver disease after PD may be at risk for sustained mal-
nutrition that could reduce their tolerance to gemcitabine-
based adjuvant chemotherapy.
39
Hepatic steatosis may con-
tribute toward the high intolerance rate for adjuvant chemo-
therapy after PD that has been reported in over 30% of
patients.
40
Aside from the retrospective nature of this study, small
sample size is a potential limitation of this study. Negative
effects from hepatic steatosis were not observed in this study,
but sample size could have reduced the significance of any
detectable differences. An additional limitation includes the
method of diagnosis of NAC-associated hepatic steatosis. In
the present study, CT imaging was used to diagnose this con-
dition, which does not represent a universally accepted stan-
dard for diagnosis.
41
While the standard for diagnosis of hep-
atotoxicity is invasive liver biopsy, a strength of this study is
the uniformity of the noninvasive CT method of diagnosis
among all patients. CT assessment provides an alternative,
safe preoperative tool that can substitute for invasive liver
Table 2 Analysis of
postoperative outcomes Postoperative outcomes − Hepatic
steatosis
N (%)
+ Hepatic
steatosis
N (%)
P
value
Number of patients 103 36 --
30-day mortality 2 (2) 3 (8) 0.08
90-day mortality 2 (2) 3 (8) 0.08
Major morbidity* 15 (15) 4 (11) 0.6
Any morbidity 30 (29) 6 (17) 0.1
Pancreatic fistula** 4 (4) 3 (8) 0.3
Delayed gastric emptying 14 (14) 3 (8) 0.4
Percutaneous drain placement 3 (3) 0 (0) 0.3
Transfusion requirement 24 (24) 10 (10) 0.6
Hospital LOS (days) 8.2 (4.3) 6.6 (2.0) 0.037
Operative return 0 (0) 1 (3) 0.09
Nonhome discharge 15 (15) 2 (6) 0.2
30-day readmission 11 (11) 1 (3) 0.1
Superficial surgical site infection 5 (5) 0 (0) 0.2
Deep surgical site infection 0 (0) 0 (0) 1
Organ space infection 4 (4) 1 (3) 0.8
Pneumonia 1 (1) 0 (0) 0.6
Urinary tract infection 0 (0) 0 (0) 1
Unplanned re-intubation 2 (2) 1 (3) 0.8
Prolonged intubation (> 48 h) 1 (1) 0 (0) 0.6
Pulmonary embolism 1 (1) 0 (0) 0.6
Acute renal failure 0 (0) 1 (3) 0.09
Cardiac arrest requiring CPR 1 (1) 1 (3) 0.4
Myocardial infarction 0 (0) 1 (3) 0.09
Deep venous thrombosis 4 (4) 1 (3) 0.8
Vascular anastomotic thrombosis (patients with vascular
reconstruction)
1 (4) 1 (7.7) 0.6
Clostridium difficile 1 (1) 0 (0) 0.5
Sepsis 3 (3) 0 (0) 0.3
CPR cardiopulmonary resuscitation, LOS length of stay, Recon reconstruction
*Included pancreatic fistula grade B or C, delayed gastric emptying (grade B), interventional radiology drain
placement, sepsis, unplanned return to the operating room, myocardial infarction, cardiac arrest with CPR, acute
renal failure, pulmonary embolism, pneumonia, unplanned re-intubation, organ space infection
**Any grade (including one case of biochemical leak). Bold indicates significance
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biopsy as a marker of hepatic steatosis in patients under con-
sideration for surgery for pancreatic cancer.
Conclusion
Limited research has explored the impact of neoadjuvant
chemotherapy-associated hepatic steatosis on postoperative
outcomes after pancreatectomy. In the present study, hepatic
steatosis developed in 24% of patients who received neoadju-
vant chemotherapy. However, hepatic steatosis does not ap-
pear to be associated with increased short-term morbidity or
mortality after pancreatoduodenectomy.
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